The Future of Biofilms Treatment Market

The biofilms treatment market is segmented into debridement equipment; gauzes and dressings; gels, ointments, and sprays; wipes, pads, and lavage solutions; and grafts and matrices. The gauzes and dressings segment accounted for the largest market share in 2019. The large share of this segment is attributed to the ability of antimicrobial products to remove, prevent, and manage biofilms.

The hospitals, ASCs, and wound care centers segment accounted for the largest market in 2019. This segment is also projected to register the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the growing geriatric population and the subsequent increase in the prevalence of age-related conditions and many treatment procedures carried out in hospitals.

The biofilms treatment market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East & Africa (MEA). In 2019, North America accounted for the largest share of the biofilms treatment market. The large share of this market can be attributed to the increasing incidence of chronic wounds, rising healthcare expenditure, the introduction of novel and specialty biofilm management products, and the presence of major market players in this region.

For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=57398610

The large share of this market can be attributed to the increasing incidence of chronic wounds, rising healthcare expenditure, the introduction of novel and specialty biofilm management products, and the presence of major market players in this region.

Key Market Players

Prominent players in the biofilms treatment market include Smith & Nephew (UK), MiMedx Group Inc. (US), ConvaTec Group plc (UK), Coloplast A/S (Denmark), Mölnlycke Healthcare AB (Sweden), Organogenesis Holdings Inc. (US), Integra LifeSciences Holdings Corporation (US), B. Braun Melsungen AG (Germany), PAUL HARTMANN AG (Germany), Medline Industries Inc. (US), Acelity (US), Misonix (US), Zimmer Biomet Holdings Inc. (US), Kerecis (Iceland), Welcare Industries S.p.A (Italy), Medaxis AG (Switzerland), PulseCare Medical (US), Arobella Medical, LLC (UK), RLS Global AB (Sweden), Mil Laboratories Pvt. Ltd. (India).

Smith and Nephew (UK) is the leading player in the global biofilms treatment market. The company focuses on product launches and acquisitions to increase its share in the biofilms treatment market. Smith and Nephew is a pioneer in advanced wound care and has been in the market for more than 15 years, which provides it with a competitive edge. Also, the company is focusing on increasing its customer base and expanding its reach in untapped emerging markets.

Research Developments Analysis:

• In May 2020, ConvaTec announced the launch of ConvaMax, which helps in managing highly exuding wounds, including leg ulcers, surgical wounds, and diabetic foot ulcers.
• In September 2018, ConvaTec Group received US FDA 510(k) clearance for its AQUACEL Ag Advantage antimicrobial dressings.
• In 2017, Smith and Nephew launched MolecuLight i: X, a handheld wound imaging device, in Europe. This device instantly measures wound surface area and shows the presence and distribution of potentially harmful bacteria.